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ARTICLE OPEN
Metabolic programming determines the lineage-differentiation
fate of murine bone marrow stromal progenitor cells
Michaela Tencerova 1, Elizabeth Rendina-Ruedy2, Ditte Neess3, Nils Færgeman3, Florence Figeac1, Dalia Ali1, Morten Danielsen4,
Anders Haakonsson1, Clifford J. Rosen2 and Moustapha Kassem1,5
Enhanced bone marrow adipogenesis and impaired osteoblastogenesis have been observed in obesity, suggesting that the
metabolic microenvironment regulates bone marrow adipocyte and osteoblast progenitor differentiation fate. To determine the
molecular mechanisms, we studied two immortalized murine cell lines of adipocyte or osteoblast progenitors (BMSCsadipo and
BMSCsosteo, respectively) under basal and adipogenic culture conditions. At baseline, BMSCsadipo, and BMSCsosteo exhibit a distinct
metabolic program evidenced by the presence of speciﬁc global gene expression, cellular bioenergetics, and metabolomic
signatures that are dependent on insulin signaling and glycolysis in BMSCsosteo versus oxidative phosphorylation in BMSCsadipo. To
test the ﬂexibility of the metabolic program, we treated BMSCsadipo with parathyroid hormone, S961 (an inhibitor of insulin
signaling) and oligomycin (an inhibitor of oxidative phosphorylation). The treatment induced signiﬁcant changes in cellular
bioenergetics that were associated with decreased adipocytic differentiation. Similarly, 12 weeks of a high-fat diet in mice led to the
expansion of adipocyte progenitors, enhanced adipocyte differentiation and insulin signaling in cultured BMSCs. Our data
demonstrate that BMSC progenitors possess a distinct metabolic program and are poised to respond to exogenous metabolic cues
that regulate their differentiation fate.
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INTRODUCTION
Bone marrow (BM) is a heterogeneous organ that contains, in
addition to hematopoietic stem cells, BM stromal (also known as
skeletal or mesenchymal) stem cells (BMSCs) and their descendent
progenitors of adipocyte (AD) and osteoblast (OB) lineages that
give rise to BM adipose tissue (BMAT) and bone, respectively.1–5
The differentiation of BMSCs is regulated by a variety of
extracellular factors present in the BM microenvironment.3,6
Metabolic changes in obesity, type 2 diabetes, and anorexia
nervosa lead to differential effects on BMSC differentiation
capacity and are associated with increased BMAT formation,7
suggesting that the metabolic state of the organism regulates
BMSC differentiation fate.
In a number of stem cell models, such as pluripotent embryonic
stem cells, hematopoietic, muscle stem cells8–10 and immune
cells,11 cellular differentiation and functions are determined by the
cellular metabolic and bioenergetic state.12 Pluripotent embryonic
stem cells prefer anabolic glycolysis, which is also the preferred
metabolic process of rapidly proliferating cells.8,13 In addition,
hematopoietic progenitor cells exhibit differentiation-dependent
use of glycolysis or oxidative phosphorylation (OxPhos).14,15
Similarly, during extramedullary AD differentiation, a switch in
the bioenergetic program from glycolysis to OxPhos has been
observed and provides AD progenitors with sufﬁcient energy for
histone acetylation and activation of the lipogenic and adipogenic
program.16 On the other hand, during mid to late OB differentia-
tion, glycolysis is the preferred bioenergetic mechanism.17 These
data suggest that the differentiation responses of progenitor cells
to metabolic changes in their microenvironment are dependent
on their bioenergetic state and substrate choice.18 However, it is
not known whether a speciﬁc metabolic program of BMSC
progenitors exists and whether it determines their differentiation
responses.
To address this question, we employed two immortalized
murine cell lines of progenitor cells that are committed towards
either AD or OB (BMSCsadipo and BMSCsosteo, respectively) as they
represent two alternative differentiation choices of BMSCs
in vivo. These cell lines have previously been established and
characterized in our laboratory.19–21 We tested the hypothesis
that there exists a distinct metabolic program in BMSC
progenitors that determines their differentiation responses to
exogenous metabolic cues. Applying the global approaches of
transcriptional and metabolomics analyses, we demonstrate that
AD versus OB progenitors exhibit a unique bioenergetic proﬁle
and intrinsic metabolic program that is responsive to the
exogenous cue of insulin and regulates their differentiation
outcome. We corroborated these ﬁndings by reporting similar
changes in BMSC differentiation capacity in vivo under condi-
tions of metabolic changes related to high-fat diet (HFD)-induced
obesity in mice.
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RESULTS
BMSCsadipo and BMSCsosteo progenitors exhibit a unique gene
expression proﬁle
BMSC cultures represent a heterogeneous population of cells that
include stem cells and their descendent progenitors at different
stages of differentiation.4,22 To avoid confounding variables
mediated by different cell populations present within primary
cultures, we employed two immortalized murine lines that were
functionally deﬁned by their ability to differentiate into either AD
(BMSCsadipo) or OB (BMSCsosteo)19 (Fig. 1a). To identify the
presence of a molecular signature of bioenergetic and metabolic
programs, we performed global gene expression proﬁling under
basal conditions20,21 that revealed differential enrichment of
genes associated with the following metabolic pathways: insulin
signaling, PPAR signaling, fatty acid oxidation, glycolysis and cell
adhesion, cell cycle, immune system, and purine metabolism in
BMSCsadipo versus BMSCsosteo (Fig. 1b and Fig. S1). Concordant
changes in the expression of a representative group of genes were
conﬁrmed by qRT-PCR (Fig. 1c–k). Compared with BMSCsosteo,
gene expression proﬁling of BMSCsadipo revealed increased
expression of insulin-responsive genes (Irs1, Irs2, Insr, and Foxo1)
(Fig. 1c), glucose transporters (Glut4) (Fig. 1d), adipocytic genes
(Pparγ2, C/epbα, Lep, and Adipoq) (Fig. 1e), lipid metabolism genes
(Fsp27, Cidea, Cd36, and Hsl) (Fig. 1f), autophagy (Atg7, Lc3b, and
Beclin1) (Fig. 1g), bioenergetic genes (Ucp, Prdm16, Mttp, and
Pparα) (Fig. 1h), inﬂammatory genes (Il1β, Tnfα, and Lcn2) (Fig. 1i),
and senescence-associated markers (p21, p53, Fasl, Hmox1, and
Sod2) (Fig. 1j). As expected, BMSCsadipo expressed lower levels of
osteoblastic genes (Fig. 1k). We employed this molecular signature
to test the ﬂexibility of the BMSCsadipo and BMSCsosteo phenotypes
in response to adipogenic culture conditions that promote AD
differentiation. As shown in Fig. S2a–e, adipogenic culture
conditions promoted AD formation only in BMSCsadipo but not
in BMSCsosteo. In addition, the gene expression proﬁle of
adipocytic genes and genes associated with insulin signaling,
glucose transporter, lipid metabolism, and autophagy were
enhanced in BMSCsadipo but not in BMSCsosteo. On the other
hand, BMSCsosteo exhibited higher gene expression levels of OB
marker genes (Oc, Alpl, Bmp2, and Pth1r), which were more robust
in the presence of OB differentiation induction medium, along
with increased Alkaline phosphatase (ALP) activity and no effect
on adipocytic marker genes in compared with those in BMSCsadipo
(Fig. 1k, Fig. S2f–h). These data corroborate that BMSCsadipo and
BMSCsosteo progenitors are committed progenitors poised to
respond to metabolic and nutrient stimuli and that they exhibit
signiﬁcant differences in the gene expression levels of metabolic
and bioenergetic genes.
BMSCsadipo and BMSCsosteo progenitors exhibit differential
responses to insulin
To investigate the responsiveness of BMSCsadipo and BMSCsosteo to
the metabolic environment, we determined the responses to
insulin as the major regulator of cellular energy metabolism.
BMSCsadipo exhibited higher levels of insulin signaling genes (Fig.
1c) and enhanced responsiveness to insulin compared with those
of BMSCsosteo as measured by pAKT(Ser-473)/total AKT (Fig. 2a, b
and Fig. S3a, b, left panels), and this occurs at baseline and when
cultured under adipogenic conditions. In addition, insulin receptor
(INSR) protein levels were higher in BMSCsadipo compared with
BMSCsosteo (Fig. 2a, b, Fig. S3a, b, right panels).
BMSCsadipo exhibit higher insulin-dependent glucose utilization
and de novo lipogenesis compared with those of BMSCsosteo
Since BMSCsadipo were more insulin-responsive at baseline and
under adipogenic conditions, we investigated functional insulin
responses in the two immortalized progenitor cell lines (Fig. 2c, d).
BMSCsadipo were more responsive to insulin stimulation, as
reﬂected by the higher glucose uptake under baseline and
adipogenic culture conditions (Fig. 2c, d). In addition at baseline,
glucose uptake (Fig. 2c, d) was higher in BMSCsosteo compared
with uptake in BMSCsadipo.
At baseline, de novo synthesized lipids determined by thin layer
chromatography (TLC) analysis were undetectable (data not
shown), while following treatment with adipogenic culture
conditions, BMSCsadipo exhibited higher levels of insulin-
mediated glucose incorporation into fatty acids (FA) and
triglyceride (TG) (Fig. 2e, f), which was similar to what was
observed in 3T3-L1 cells.23 BMSCsosteo did not accumulate lipids
(Fig. 2e, f). Additional studies employing radiolabeled 14C glucose
detected the incorporation of glucose into lipids (FA and TG),
demonstrating de novo lipogenesis in BMSCsadipo and 3T3-L1 but
not in BMSCsosteo under adipogenic culture conditions (Fig. 2g, h).
BMSCsadipo and BMSCsosteo exhibit a distinct bioenergetic proﬁle
Since BMSCsadipo and BMSCsosteo exhibit well-deﬁned differences
in their metabolic molecular signature and insulin responsiveness,
we investigated the functional consequences on their bioener-
getic proﬁle using a Seahorse XF24® analyzer. The cells were
studied under the basal state and following incubation in
adipogenic culture conditions. We obtained simultaneous mea-
surements of mitochondrial function via the oxygen consumption
rate (OCR) and glycolysis via the extracellular acidiﬁcation rate
(ECAR) employing the Glyco and Mito Stress test (Fig. 3).
In the Glyco Stress test, ECAR revealed higher basal glycolytic
activity and maximal glycolytic capacity in BMSCsosteo compared
with those in BMSCsadipo, and this was observed both at baseline
(Fig. 3a) and following incubation under adipogenic culture
conditions (Fig. 3b). On the other hand, the Mito Stress test
showed similar OxPhos activity at baseline between BMSCsosteo
and BMSCsadipo (Fig. 3c, left panel). In addition, BMSCsosteo
maintained higher glycolytic activity (Fig. 3c, right panel).
Following 10 days of incubation under adipogenic culture
conditions, BMSCsadipo demonstrated elevated basal OCR, and
following mitochondrial uncoupling with carbonyl cyanide-4-
(triﬂuoromethoxy) phenylhydrazone (FCCP), their maximal OCR
was dramatically increased (Fig. 3d, left panel). Conversely,
BMSCsosteo exhibited reduced basal and maximal OCR (mitochon-
drial respiration) (Fig. 3d, left panel) while maintaining higher
glycolytic activities (Fig. 3d, right panel). Furthermore, when
BMSCsadipo and BMSCsosteo were exposed to insulin (100 µmol·L–1),
they exhibited signiﬁcant differences in their bioenergetic proﬁle
with enhanced OxPhos in BMSCsadipo and not in BMSCsosteo that
maintained a glycolytic proﬁle (Fig. 3e, f).
These data demonstrate that BMSCsadipo exhibit a distinct
bioenergetic proﬁle associated with different strategies for
glucose utilization compared with that of BMSCsosteo.
BMSCsadipo and BMSCsosteo exhibit signiﬁcant differences in their
metabolite composition
To corroborate the observed changes in the bioenergetic proﬁle,
we performed a global metabolomic comparison of BMSCsadipo
and BMSCsosteo in undifferentiated conditions using liquid
chromatography–mass spectrometry (LC–MS) (Fig. 4). A heat
map of intracellular metabolites revealed a unique proﬁle with
signiﬁcant differences detectable at baseline (Fig. 4a). We found
that adenosine-5′-monophosphate, guanosine-5′-monopho-
sphate, uridine-5′-monophosphate, glutamine, and glucose-6-
phosphate were the major metabolites that distinguish
BMSCsadipo from BMSCsosteo, suggesting that purine/pyrimidine
and glucose metabolism are key processes associated with AD
lineage commitment. On the other hand, the major metabolites in
BMSCsosteo were proline, choline, glyceraldehyde, and serine,
which may be related to the capacity for extracellular matrix
production (Fig. 4b).
Additional targeted analysis of metabolites using LC–MS
identiﬁed several speciﬁc compounds, such as phosphocholine,
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Fig. 1 BMSCsadipo and BMSCsosteo progenitors exhibit a unique gene expression proﬁle. a Representative pictures of BMSCsadipo and
BMSCsosteo with mitochondrial staining using MitoTracker (red), Alizarin staining (AZR) for matrix mineralization and Oil Red O staining (ORO)
showing the morphological and differentiation-induced differences between the murine cell lines. b Enrichment of genes of functional GO
categories from microarray. Gene expression proﬁling in BMSCsadipo (white bars) and BMSCsosteo cultured in basal conditions (black bars):
c genes involved in insulin signaling such as Irs1, Irs2, Insr, Igfr1, and Foxo1; d glucose transporters such as Glut1, Glut2, Glut3, and Glut4;
e adipocytic genes such as Pparγ2, C/ebpα, Lep, LepR, and Adipoq; f genes involved in lipid metabolism such as Fsp27, Cidea, Cd36, and
Hsl; g autophagy genes such as Atg7, Lc3b, Beclin1, and Lamp1; h bioenergetic genes such as Ucp1, Ucp2, Ucp3, Prdm16, Mttp, and Pparα;
i inﬂammatory genes such as Il1β, Tnfα, Mcp1, RelA, and Lcn2; j senescence-associated markers such as p21, p53; Fasl, Serpine1, Serpineb2, Hmox1,
and Sod2; k osteoblast marker genes such as Oc, Opn, Alpl, Bmp2, and Pthr1. Data are presented as the mean fold change (F.C.) of gene
expression normalized to BMSCsadipo expression ± SEM, (n= 3 per group); (*P < 0.05, **P < 0.01; ***P < 0.001: BMSCsadipo vs BMSCsosteo, two-
tailed unpaired Student’s t test)
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Fig. 2 BMSCsadipo and BMSCsosteo progenitors exhibit differential responses to insulin. Representative western blot to evaluate insulin-
stimulated (100 nmol·L–1, 15 min) phosphorylation of AKT (p-S473AKT) and total AKT, INSRβ a in undifferentiated BMSCsadipo and BMSCsosteo
and b BMSCsadipo and BMSCsosteo differentiated cells in adipogenic conditions (n= 3). Insulin-stimulated glucose uptake using a 14C glucose
tracer after a 24-h incubation c in undifferentiated (baseline) BMSCs and d BMSCs differentiated under adipogenic conditions from BMSCsadipo
and BMSCsosteo. Data are presented as the mean of glucose uptake normalized to the baseline of murine 3T3-L1 ﬁbroblasts as a positive
control ± SEM from three independent experiments. (*P < 0.05, **P < 0.01: BMSCsadipo vs BMSCsosteo, two-tailed unpaired Student’s t test; #P <
0.05: nonstimulated vs insulin-stimulated cells). Proﬁle of neutral lipids in BMSCsadipo, BMSCsosteo, and 3T3-L1 cells under insulin stimulation
(100 nmol·L–1) using thin layer chromatography (TLC): e densitometry of triglycerides (TG) and f the the fatty acid (FA) content in BMSC
differentiated cells under adipogenic conditions. Densitometry of 14C FA (g) and 14C TG (h) incorporation in BMSC differentiated cells under
adipogenic conditions. Data are presented as the mean of F.C. ± SEM from three independent experiments. (n= 3) (*P < 0.05, **P < 0.01:
BMSCsadipo vs BMSCsosteo, one-way ANOVA)
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Fig. 3 BMSCsadipo and BMSCsosteo exhibit a distinct bioenergetic proﬁle deﬁning their metabolic program. Bioenergetic proﬁling of
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measuring glycolytic function in cells; a basal and maximal glycolytic capacity in BMSCsosteo compared with capacities in BMSCsadipo in basal
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and differentiated BMSCsadipo and BMSCsosteo in a Mito stress test measuring mitochondrial respiration in cells. c Representative graph of OCR
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CPD-choline, serine, and glutathione, which were enriched in
BMSCsosteo versus BMSCsadipo (Fig. 4c). On the other hand, xanthine
and hypoxanthine were more abundant in BMSCsadipo compared
with BMSCsosteo, suggesting changes in membrane lipid content
that affect intracellular signaling and the levels of reactive oxygen
species.24 Additional metabolites that showed differences between
the two immortalized cell lines included glyceraldehyde and
glutamic acid, supporting the presence of higher glycolytic activity
in BMSCsosteo. In addition, amino acid metabolites were different in
BMSCsadipo compared with BMSCsosteo, e.g., higher glutamine in
BMSCsadipo, which can serve as an alternative carbon source for
OxPhos.25
A similar distinct pattern of metabolites was identiﬁed in the
metabolomic analysis of intracellular metabolites of BMSCsadipo
and BMSCsosteo following 24 h and 72 h of in vitro culture in basal
conditions (Figs. S4 and S5), corroborating the presence of a stable
metabolic program.
Is the metabolic program of BMSC progenitors ﬂexible? Effects of
parathyroid hormone (PTH) and inhibitors of insulin signaling and
OxPhos
Our study demonstrated that committed adipocytic and osteo-
blastic cells exhibit a distinct metabolic program leading to
differential responses under adipogenic culture conditions.
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However, it is not known whether these responses can be
regulated by external cues. Thus, we studied the effects of
treatment with PTH on AD differentiation when the cells were
cultured under adipogenic culture conditions. PTH is known to
enhance OB differentiation of progenitor cells through inducing
changes in the bioenergetic proﬁle.26 Gene expression proﬁling
revealed that the expression level of PTH receptor 1 (Pth1r) was
higher in BMSCsosteo compared with the level in BMSCsadipo
(Fig. 1k). In vitro treatment of BMSCsadipo and BMSCsosteo with PTH
under adipogenic culture conditions for up to 10 days led to
reduced AD differentiation in BMSCsadipo, as evidenced by the
decreased number of Nile Red-positive mature ADs and reduced
expression levels of adipocytic genes (Pparγ2 and Fsp27) (Fig. 5a,
b). On the other hand, we observed increased expression of the
PTH-responsive genes Bmp4, Igf1, and Igfr1 in BMSCsosteo but not
in BMSCsadipo (Fig. 5c). Furthermore, PTH treatment impaired
insulin signaling accompanied by decreased Insr gene expression
in BMSCsadipo (Fig. 5d), which corroborates similar ﬁndings
previously reported in 3T3-Ll cells.27 In addition, PTH treatment
altered the bioenergetic program of BMSCsadipo, shifting the cells
towards a more glycolytic state (Fig. 5e), as we observed increased
“induced glycolysis” in the presence of PTH (PTH-treated versus
Veh-treated cells, 22%, P < 0.05) (Fig. 5e, left graph). In addition,
PTH treatment induced a shift toward more glycolytic ATP
production, even though mitochondrial ATP production was also
affected (Fig. 5e, right graph).
We also tested whether manipulation of insulin signaling in
BMSCsadipo affects their differentiation state. Treatment of
BMSCsadipo with the INSR antagonist S961 (100 nmol·L–1) under
adipogenic culture conditions for 10 days resulted in impaired AD
differentiation as evaluated by Nile Red staining (Fig. 6a), reduced
gene expression of adipocytic genes (Pparγ2, Fsp27, and Irs1)
(Fig. 6b) and impaired insulin signaling as well as decreased Insr
gene expression (Fig. 6c). S961 treatment changed basal
metabolism in BMSCsadipo, as shown by a reduced glycolytic and
enhanced OxPhos ATP production rate. In addition, based on ATP
levels, S961 treatment increased ATP production in BMSCsadipo to
comparable levels as those observed in BMSCsosteo (Fig. S6a).
Finally, we tested whether inhibition of OxPhos in BMSCsadipo
affects the differentiation capacity of cells. We treated BMSCsadipo
with oligomycin (100 nmol·L–1) (an inhibitor of ATP-synthase, a key
enzyme in mitochondrial respiration) for 10 days in the presence
of adipogenic culture conditions. As shown in Fig. 6d, oligomycin
treatment decreased the AD differentiation capacity as evidenced
by a decreased number of mature ADs that were positive for Nile
Red staining, decreased gene expression of adipocytic and insulin
signaling-related genes (Pparγ2, Fsp27, and Irs1) (Fig. 6e) and
reduced insulin signaling along with decreased Insr gene
expression (Fig. 6f). Moreover, oligomycin treatment exhibited
modest effects on ATP production in BMSCsadipo under basal
undifferentiated culture conditions. However, under adipogenic
induction, oligomycin signiﬁcantly increased ATP production via
glycolysis and reduced OxPhos (Fig. S6a, b).
Next, we examined the effect of S961 and oligomycin treatment
on OB differentiation. S961 did not exert additional effects on
enhanced OB differentiation in BMSCsosteo as determined by
in vitro mineralized matrix formation, even though we observed a
signiﬁcant increase in the osteoblastic genes Alpl and Bmp2
(Fig. S6c). Oligomycin signiﬁcantly inhibited OB differentiation of
BMSCsosteo, which was also accompanied by inhibition of cell
proliferation following longer in vitro exposure (Fig. S6d).
Thus, these data demonstrate that targeting the metabolic
program in BMSC progenitors modulates their differentiation capacity.
In vivo changes in the BM microenvironment induced by a HFD
regulate AD and OB progenitor formation
To determine the physiological relevance of our ﬁndings, we
employed the molecular signature of BMSCsadipo to investigate
the in vivo response of BMSC progenitors to the “obesogenic”
environment present in C57BL/6 mice fed for 12 weeks with a HFD
(60% fat)28 that resulted in obesity, hyperinsulinemia, and
increased BM adiposity and AD size in the BM (Fig. S7a–c). In
vitro cultures of BMSCs obtained from HFD-fed mice when
compared with BMSCs obtained from mice on a normal diet (ND)
exhibited a signiﬁcant decrease in the number of BMSCs that are
CD73+ and Sca+/CD140a+ and a concomitant increase in the
expression of the adipocytic progenitor markers (mRNA and
protein levels) CD80, CD141, CD53, and CD220 (Fig. 7a–c, Fig. S7d),
which have previously been reported to be enriched in BMSCsadipo
compared with BMSCsosteo 21 (Fig. S7e). These ﬁndings were
accompanied by upregulation of adipocytic gene markers (Pparγ2,
C/ebpα, Fsp27, CD36, and Adipoq) and no changes in osteoblastic
gene markers, suggesting expansion of BMSC AD progenitors (Fig.
7d). In addition, the colony forming unit-ﬁbroblast (CFU-f) capacity
of primary cultures of BMSCs was decreased in HFD-fed mice
(Fig. S7f). Furthermore, exposing BMSCs obtained from HFD mice
to adipogenic conditions in vitro led to increased AD differentia-
tion (Fig. 7e), increased expression of adipocytic genes (Pparγ2,
Adipoq, Fsp27, and Lep) and no effect on OB differentiation (Fig.
7f). In addition, similar to our observations in BMSCsadipo, cultured
BMSCs obtained from HFD mice revealed enhanced responsive-
ness to insulin compared with that of BMSCs obtained from ND
mice (Fig. 7g, h). Thus, these data demonstrate the expansion of a
population of adipocytic progenitors in BM following HFD-induced
obesity that is similar in phenotype and functional responses to
BMSCsadipo.
DISCUSSION
In this study, we demonstrate that BMSC progenitors display a
distinct metabolic program that determines their differentiation
fate. AD progenitors exhibit enhanced insulin signaling and a
higher capacity for OxPhos and lipid storage, whereas OB
progenitors exhibit reduced insulin signaling, utilization of
glycolytic activity to generate energy and an absence of lipid
storage. We also demonstrate that targeting the AD progenitors’
metabolic program can regulate the efﬁciency of differentiation.
The physiological relevance of these ﬁndings was corroborated
in vivo through an intervention model of HFD-induced obesity in
mice that led to expansion and enhanced differentiation of
adipocytic progenitors.
Cellular metabolic programing refers to the metabolic processes
that not only provide energy for cellular homeostatic functions
but also deﬁne the cellular phenotype by mediating changes in
posttranslational modiﬁcations of histones and transcription
factors.9 Their metabolites could participate in posttranslational
modiﬁcation of the genome by methylation of transcription factor
promoters, which has been shown in muscle- or adipose-derived
stem cells.9,29 Stem cells in different states of commitment have
speciﬁc bioenergetic needs that are necessary for their functions;
thus, their differentiation can be affected under different
pathophysiological conditions related to the metabolic status of
the organism. Changes in cellular metabolic programming have
been reported to occur during the initial phases of somatic cell
programming to pluripotent stem cells and during immune cell
differentiation.8,10,11 However, limited information is available
regarding the relationship between the metabolic phenotype and
lineage-committed BMSC OB and AD progenitors.
Employing two functionally different murine progenitor cell
lines of AD progenitors (BMSCsadipo) and OB progenitors
(BMSCsosteo), we observed a distinct metabolic gene signature of
BMSCsadipo characterized by enrichment in genes of insulin
signaling, autophagy, lipid metabolism, and glucose utilization,
suggesting the presence of a hypermetabolic state. On the other
hand, BMSCsosteo were enriched in skeletal-associated genes and
extracellular matrix genes that are relevant to their role in matrix
Metabolic programming in bone marrow progenitors
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production and bone formation. This molecular phenotype
suggests that BMSC progenitors mediate their differentiation
functions in response to exogenous metabolic cues. These data
corroborate recent ﬁndings from our group, reporting expansion
of adipogenic progenitors in BMSC cultures of obese subjects
along with enhanced insulin signaling.30
Progenitor cell clonal expansion requires the availability of a
quick source of energy, and glycolysis is the preferred energy
production mechanism, whereas the more energy efﬁcient
oxidative metabolism is associated with cell differentiation and
mature functions.9 We observed a different metabolic pattern in
BMSC progenitors. Committed osteoblastic progenitors employed
glycolysis and, to a lesser degree, OxPhos, but committed
adipocytic progenitors employed mainly OxPhos. This phenom-
enon has also been observed in undifferentiated versus differ-
entiated pluripotent stem cells.31 The higher glycolytic proﬁle of
BMSCsosteo represents a similarity with the stem cell state, while
the higher OxPhos rate in BMSCsadipo is associated with a more
differentiated phenotype. It is plausible that glycolysis is preferred
in committed osteoblastic cells because it is a source of rapid
energy generation needed by the cells to respond quickly during
bone regeneration following bone fracture or during bone
remodeling. In addition, osteoblastic progenitors are present near
the bone surface in a hypoxic microenvironment in which HIF1α is
inducible and can drive the glycolytic processes.32,33 Our study
corroborates the ﬁndings of a recent study by Guntur et al.34
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demonstrating that glycolysis is a major metabolic process during
OB differentiation in a murine osteoblastic cell line MC3T3, in
contrast to a committed preadipocytic cell line, 3T3-L1, which
preferred OxPhos during AD differentiation. Thus, commitment to
either OBs or ADs is associated with a characteristic bioenergetic
proﬁle that is maintained during differentiation.
Nutrient-sensitive signaling pathways (mTOR, AMPK, or insulin/
IGF-1) contribute to stem cell fate determination and energy fuel
choice.35 Glucose is transported into the cells via glucose
transporters (GLUT) that vary among different cell types.36 During
skeletal development, glucose uptake is mediated primarily via
GLUT1, which is insulin-independent.37 In our study, we observed
that postnatal BM AD BMSCsadipo progenitors expressed higher
levels of insulin-responsive GLUT4 compared with BMSCsosteo,
suggesting a higher responsiveness to insulin. This was further
conﬁrmed by the presence of enhanced insulin-stimulated
glucose uptake in AD progenitors and signiﬁcant changes in the
metabolic phenotype in response to the acute effect of insulin
BMSCsadipo
BMSCsadipo
150
150
100
50
0 0
0.5
1.0
50
0
100
Nile red
staining/%
150
50 50 000
40 000
30 000
20 000
10 000
0
40
30
20
10
0
AD
OL
IGO OLIGO
OLIGO 50
0
100
10
8
6
6
4
4
2
2
0
0
Nile red
staining/%
0
5
10
15
20
25
Ppar2 expression (F.C.) Fsp27 expression (F.C.) Irs1 expression (F.C.)
Ppar2 expression (F.C.) Fsp27 expression (F.C.) Irs1 expression (F.C.)
Insr expression (F.C.)
Insr expression (F.C.)
AD
AD
AD
S961
S961
S961 - 10 100
- 10 100
OLIGO - 10 100
- 10 100 - 10 100
S961 - 10 100
S961 - 10 100 S961 - 10 100
pAKT S473
Total AKT
100 nmol·L-1 INS
S961 100 nmol·L-1
β-actin
pAKT S473
Total AKT
100 nmol·L-1 INS
Oligomycin
/100 ng·mL-1
Oligo/100
ng·mL-1
β-actin
-
- -
-
- -
- -+ +
+ + + +
++
-
- -
-
- -
- -+ +
+ + + +
++
*1.0
1.00.5
0.5
0.8
0.6
0.4
0.2
0
1.5
0
0
D
en
si
to
m
et
ry
 (F
.C
.)
pAKT/total AKT
INS- INS+
CT
INS- INS+
D
en
si
to
m
et
ry
 (F
.C
.)
pAKT/total AKT
INS- INS+
CT
INS- INS+
S961
100 nmol·L-1
*** ***
***
**
**
*
*** ***
*** ***
*
*
**
**
**
a b
c
d e
f
Fig. 6 Blocking insulin receptor signaling and oxidative phosphorylation affects the adipogenic potential of BMSCsadipo progenitors.
a Representative pictures and evaluation of Nile Red staining in BMSCsadipo differentiated in adipogenic conditions (AD) and after
100 nmol·L–1 S961 (insulin receptor antagonist) treatment (D10), (scale bar 100 μm); b Gene expression of adipocytic and insulin signaling-
related genes such as Pparγ2, Fsp27, and Irs1 after S961 treatment; data are presented as the mean of the fold change (F.C.) over
undifferentiated cells ± SEM, (n= 3); c representative western blot and densitometry of insulin-stimulated (100 nmol·L–1, 15 min)
phosphorylation of AKT (p-S473AKT) and total AKT and gene expression of Insr in BMSCsadipo treated with S961 100 nmol·L–1; (n= 3);
d representative pictures and evaluation of Nile Red staining in BMSCsadipo differentiated in adipogenic conditions (AD) and after 100 ng·mL–1
oligomycin (inhibitor of ATP-synthase) treatment (D7), (scale bar 100 μm); e gene expression of adipocytic and insulin signaling-related genes
such as Pparγ2, Fsp27, and Irs1 after oligomycin treatment; data are presented as the mean fold change (F.C.) over undifferentiated cells ± SEM,
(n= 3); f representative western blot and densitometry of insulin-stimulated (100 nmol·L–1, 15 min) phosphorylation of AKT (p-S473AKT) and
total AKT and gene expression of Insr in BMSCsadipo treated with oligomycin 10 and 100 ng·mL–1; (n= 2–3); (*P < 0.05, **P < 0.01; ***P < 0.001:
CT vs treated cells; two-tailed unpaired Student’s t test)
Metabolic programming in bone marrow progenitors
M Tencerova et al.
9
Bone Research            (2019) 7:35 
100
120
100
80
60
40
20
0
5
25
20
15
5
0
10
25
ORO
20
15
5
0
10
Adipocytic progenitor CD markers
Adipocytic progenitors CD markers BMSCs undifferentiated
BMSCs undifferentiated
BMSCs differentiated in AD
condition
BMSCs differentiated in OB
condition
BMSCs in AD condition
4
3
2
1
0
4
3
2
20
10
0
15
5
1
0
**
*
*
**
**
*
*
*
*
*
*
*
*
*
*
*
a b
dc
e f
g h
ND
HFD
ND
HFD
ND
HFD
ND
ND
ND
- -+ +
- + + - + +
+ +
HFD ND
HFD
HFD
ND
CT
CT
INS
INS 100 nmol·L-1
Total AKT
pAKT/total AKT
pAKT 473
INS 100 nmol·L-1
Total AKT
pAKT 473
HFD ND
AD
HFD
HFD
ND HFD
ND
HFD
CD9
0
CD5
3
CD8
0
CD1
41
CD2
20
Pp
ar
2
Pp
ar
2
Fs
p2
7
Fs
p2
7
CD
36
Ad
ipo
q
Ad
ipo
q
Le
p
Le
p
Ru
nx
2
Ru
nx
2
OC
OC
Bm
p2
Bm
p2
Alp
l
Alp
l
C/E
BP
α
CD5
3
CD8
0
CD1
41CD7
3
Sca
1/C
D14
0a
Po
si
tiv
e
 c
e
lls
/%
Po
si
tiv
e
 c
e
lls
/%
G
en
e 
ex
pr
es
sio
n 
(F.
C.
)
G
en
e 
ex
pr
es
sio
n 
(F.
C.
)
G
en
e 
ex
pr
es
sio
n 
(F.
C.
)
D
en
si
to
m
et
ry
 (A
.U
.
)
G
en
e 
ex
pr
es
sio
n 
(F.
C.
)
80
60
40
20
0
Fig. 7 In vivo changes in the bone marrow microenvironment induced by a high-fat diet (HFD) regulate adipocyte and osteoblast progenitors.
a Screening of stem cell marker expression measured by ﬂow cytometry in primary BMSCs isolated from mice fed with an ND or HFD for 12 weeks
(n= 5 per group). b Gene expression of adipocytic progenitor CD markers (CD53, CD80, and CD141); and c ﬂow cytometry of adipocytic CDmarkers
(CD53, CD80, CD141, and CD220) in BMSCs obtained from ND and HFD mice (n= 6 per group). Data are presented as the mean of the fold change
(F.C.) normalized to ND BMSC gene expression ± SEM; *P < 0.05: ND vs HFD, two-tailed unpaired Student’s t test. d Gene expression proﬁle of
adipocytic genes (Pparγ2, C/ebpα, Fsp27, CD36, Adipoq, and Lep) and osteoblastic genes (Runx2, OC, Bmp2, and Alpl) presented as the fold change in
BMSCs of ND and HFD mice (n= 6 per group); e representative pictures of AD differentiation (day 10) visualized with Oil Red O staining in BMSCs
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when compared with BMSCsosteo. Our data corroborate and
extend the results of Li et al.38 that different GLUT are utilized by
murine bone cells depending on their developmental stage.
Is it possible to change lineage fate through targeting the
metabolic program of BMSC committed progenitors? We
observed that PTH treatment, inhibitors of insulin signaling and
OxPhos affected the cellular metabolism of AD progenitors and
inhibited their differentiation. Recent studies support the
observed effects in our study. Fan et al.26 demonstrated that
PTH/PTH1r signaling regulates BMSC cell fate and enhances OB
lineage commitment. Similar to our ﬁndings, Esen et al. showed
that PTH promotes OB differentiation by enhancing glycolysis,39
and Maridas et al. reported40 PTH-enhancing effects on BMAT
lipolysis. Here, we also presented additional evidence that
targeting insulin signaling or OxPhos can inﬂuence the differ-
entiation fate of BMSC progenitors. While targeting insulin
signaling in BMSC progenitors showed an opposite effect on AD
and OB differentiation, inhibition of OxPhos by a long exposure of
oligomycin negatively affected both BMSCsadipo and BMSCsosteo
progenitors during differentiation. However, further studies are
needed to investigate whether acute treatment with oligomycin
exhibits a similar effect. As previously shown by Kim et al.41 and
Guntur et al.,34 OBs may use OxPhos during their differentiation,
and depending on the source of fuel, either FA or glucose, this was
stimulated or inhibited.
Our ﬁndings suggest that BMSC progenitors exhibit a metabolic
program upstream of differentiation and not, as commonly
assumed, that as progenitors differentiate, they acquire changes
in their metabolic program. This difference is important in
clarifying the role of BM ADs in whole body energy metabolism
and bone homeostasis.
An inverse relationship between BMAT and bone mass has been
observed in several studies. However, analysis of the published
data shows that in many situations, BMAT and bone mass can
change independently.7 Our study provides a cellular explanation
for these differences, as it demonstrates the presence of AD and
OB progenitors within the BM microenvironment that respond
differently to external stimuli as well as to the metabolic status of
the organism. In hyperinsulinemic, hyperglycemic, and hyperlipi-
demic conditions using HFD-fed mice, we and others42 showed
expansion of adipocytic progenitors in the BM microenvironment.
In addition, our data advance the concept that osteoblastic and
adipocytic mature cell formation can be regulated not only at the
level of stem cells but also at the level of committed progenitors.
For translational medicine, manipulation of metabolic pathways in
BMSC progenitors is a plausible approach to enhance lineage-
speciﬁc differentiation and tissue regeneration.
MATERIALS AND METHODS
Cell culture of MSC clonal cell lines (BMSCsadipo and BMSCsosteo)
The murine BM-derived spontaneously immortalized clonal cell
lines BMSCsadipo and BMSCsosteo were established and character-
ized previously in our laboratory (for more information, see
papers19,20). For expansion, both cell lines were cultivated in basal
DMEM supplemented with 10% fetal bovine serum (FBS; Gibco
Invitrogen, USA) and 100 μg·mL–1 streptomycin and 100 U·mL–1
penicillin.
Microarray analyses
BMSCsadipo and BMSCsosteo were cultured under standard culture
conditions as described above. Total RNA was isolated at day 0 to
perform global gene expression analysis using Affymetrix
GeneChip® MG430A 2.0 Arrays (Affymetrix, USA) (GEO accession
number: GSE124905). These data were published in a previous
publication by Taipaleenmäki et al.20 We performed addition
analyses to compare global gene expression in basal conditions
to determine the GO categories of the genes that were
differentially expressed between BMSCsadipo and BMSCsosteo
(Fig. 1b and Fig. S1).
AD differentiation
For in vitro AD differentiation, the cells from both cell lines were
seeded at a density of 20 000 cells·cm–2 and incubated in DMEM
supplemented with 9% horse serum and ADinduction medium
containing 3 μg·mL–1 insulin (Sigma), 1 × 10−6 mol·L–1 dexametha-
sone, and 0.5 μmol·L–1 3-isobutyl-1-methylxanthine (IBMX; Sigma).
The medium was changed every second day for 10 days. The ADs
were visualized by Oil Red O staining.
Oil Red O staining
Cells were ﬁxed in 4% paraformaldehyde for 10 min at room
temperature (RT) and then stained with Oil Red O (Sigma-Aldrich)
to visualize the lipid content. Brieﬂy, cells were rinsed in 3%
isopropanol solution and stained with ﬁltered Oil Red O solution
(0.5 g in 100% isopropanol) for 1 h at RT.
Nile red staining
Nile red ﬂuorescence quantiﬁcation of adipogenesis was per-
formed using a stock solution of Nile red (1 mg·mL–1) in DMSO.
Staining was performed on unﬁxed cells. Cultured differentiated
cells were grown in polystyrene ﬂat‐bottom 96‐well tissue culture
(TC)‐treated black microplates and washed once with PBS. The dye
was directly added to the cells (5 μg·mL–1 in PBS) and incubated
for 10 min at RT, and then the cells were washed twice with PBS.
The ﬂuorescence intensity was measured using a microplate
reader with the bottom well‐scan mode, during which nine
readings were taken per well using excitation (485 nm) and
emission (572 nm) spectra.
OB differentiation
The cells were plated at a density of 20 000 cells·cm–2 in alpha MEM
medium (Gibco) containing 10% FBS, 100 U·mL–1 penicillin (Gibco),
100 g·mL–1 streptomycin (Gibco). One day after seeding, the
medium was replaced with OB induction medium composed of
base medium supplemented with 10mmol·L–1 B-glycerophosphate
(Sigma-Aldrich), 10 nmol·L–1 dexamethasone (Sigma-Aldrich) and
50 μg·mL–1 vitamin C (Sigma-Aldrich). The medium was changed
every other day for 10 days.
ALP activity assay
Cells were incubated with naphthol AS-TR phosphate solution
containing Fast Red TR (Sigma-Aldrich) as described previously.43
ALP activity was measured using p-nitrophenyl phosphate (Fluka
Chemie) as the substrate.44
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from the cells using TRIzol (Invitrogen)
following the manufacturer’s protocol. The RNA concentration was
measured using a Nanodrop 2100, and cDNA synthesis was
performed from 1 μg of total RNA using a commercial revertAid
H minus ﬁrst strand cDNA synthesis kit (Fermentas, Helsingborg,
Sweden) according to the manufacturer’s instructions. Gene
expression was analyzed by qRT-PCR using IQ SYBR Green Master
Mix with the ABI Step One Plus Real-Time PCR System (Applied
Biosystems) according to the manufacturer’s instructions. A list of
primers used is given in Table S1. qPCR data were normalized to
the housekeeping gene 36B4 expression and calculated using the
formula 2−(ΔΔCt) in which ΔΔCt= (Ct mRNA− Ct 36B4)sample− (Ct
mRNA− Ct 36B4)control sample.
Western blot analyses
Cell lysates were prepared using RIPA lysis buffer. Protein
concentrations were measured using the BCA assay (Thermo
Fisher). Thirty micrograms of protein was separated on 8%–12%
NuPAGE Novex Bis-Tris gels (Invitrogen) followed by transfer to a
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polyvinylidene ﬂuoride membrane (Millipore A/S). Antibodies
against the INSR and total or Ser-473 phosphorylated AKT (pAKT)
were obtained from Cell Signaling Technology (Herlev, Denmark).
Anti-β-actin was purchased from Santa Cruz Biotechnology, Inc.
(Aarhus, Denmark). Quantiﬁcation of western blots was performed
with Bio-Rad software.
Glucose uptake
Glucose uptake was measured using [1,2-3H]−2-deoxy-D-glucose
as previously described.45 The cells were starved 4 h before the
assay in basal medium without serum (DMEM/0.5% BSA). Then,
the cells were incubated in basal DMEM/0.5% BSA containing [1,2-
3H]-2-deoxy-D-glucose in the presence or absence of 100 nmol·L–1
insulin (Sigma) for 4 h and 24 h. Next, the cells were washed and
scraped in PBS buffer, and neutral lipids were separated by TLC.
The scintillation counts in cell lysates were measured on a
scintillator (PerkinElmer). The results were normalized to protein
concentrations and presented as a fold change ± SEM.
Lipid extraction and TLC
Lipids were extracted using Bligh and Dyer extraction of total
lipids from mammalian cells by adding chloroform:methanol (1:1)
solution followed by a solution of chloroform:0.2 mol·L–1 KCl,
which resulted in phase separation of the organic and aqueous
phases. The organic phase was removed and dried under
nitrogen and then resuspended in chloroform:methanol. A 20-
µL aliquot was used for scintillation measurements. The rest of
the samples were loaded in duplicate, and TLC plates were
developed to the top of the plate in the solvent system hexane:
diethylether:acetic acid (80:30:1). Lipids were visualized after
spraying the plate with 10% CuSO4 dissolved in 8% H2PO4 and
incubating in a 180 °C oven. For radioactive lipid spot visualiza-
tion, the plates were placed in cassettes (storage radioactive
screen) for 1 month in the dark and then the storage screen was
scanned on The Typhoon Scanner. Representative scan pictures
are presented as a PDF.
Bioenergetic analyses/proﬁling
BMSCsadipo and BMSCsosteo murine cell lines were seeded in 24-
well multiwell plates (Seahorse Bioscience) and differentiated as
described above. OCRs of nondifferentiated and 10-day-
differentiated cells were determined using an XF24 Extracellular
Flux Analyzer (Seahorse Bioscience). Glycolytic stress tests were
performed by sequentially adding 10mmol·L–1 glucose (and
100 nmol·L–1 insulin), rotenone and antimycin A (Rot/Ant;
1 µmol·L–1 each), carbonyl cyanide-4-(trifuoromethoxy)phenylhy-
drazone (FCCP; 2 µmol·L–1), followed by 2-deoxyglucose
(50 mmol·L–1). Conversely, a mitochondrial stress test was
performed by adding 10mmol·L–1 glucose (and 100 nmol·L–1
insulin), oligomycin A (Oligo; 2 µmol·L–1), FCCP (2 µmol·L–1), and
Rot/Ant (1 µmol·L–1 each) in succession. The basal OCR was then
calculated by subtracting Rot/Ant from the unstimulated OCR
value. Maximal respiration was determined following FCCP
treatment according to Wu et al.46 The ATP production rate was
measured by an ATP rate assay, and the acute effects of insulin
were measured by an energy phenotype test (Agilent Technolo-
gies). Data are presented as normalized to µg protein.
Metabolomics measured by LC–MC
Sample analysis was carried out by MS-Omics as follows.
Intracellular extracts were dried under nitrogen ﬂow and
reconstituted in a MilliQ water/acetonitrile (1:1) mixture. Extra-
cellular supernatants were diluted 1:3 in MilliQ water before
acetonitrile was added (1:1). The analysis was carried out using a
UPLC system (UPLC Acquity, Waters) coupled with a time of ﬂight
mass spectrometer (Xevo G2 Tof, Waters). An electrospray
ionization interface was used as the ionization source. Analysis
was performed in negative and positive ionization mode. The
UPLC was performed using a slightly modiﬁed version of the
protocol described by Paglia et al.47 Data processing was carried
out using MZmine 248 followed by curation using a custom made
in-house protocol. The compounds were identiﬁed using both
peak retention times (compared with authentic standards) and
accurate mass (with an accepted deviation of 0.005 Da). Metabo-
lomic data were analyzed using MetaboAnalyst software (www.
metaboanalyst.ca).
Treatment of BMSC progenitors with S961, PTH, and oligomycin
BMSCsadipo and BMSCsosteo were treated during their adipogenic
differentiation protocol with different reagents to test their effect
on differentiation: INSR antagonist 10 nmol·L–1 or 100 nmol·L–1 to
block insulin signaling as one of the differently activated signaling
pathways between cell lines (S961; cat. no. ABIN2876379) (www.
antibodies-online.com), PTH known to enhance OB differentiation
(1-34 fragment bovine) (Sigma; cat. no. P3671) 10 nmol·L–1 or
100 nmol·L–1, and oligomycin 10 nmol·L–1 or 100 nmol·L–1, an
inhibitor of OxPhos (Sigma, cat. no. 75351) (in independent
experiments) for 10 days. The AD differentiated cells were
harvested after 10 days for subsequent analyses. The treatments
with PTH, S961 and oligomycin were tested on mouse BMSCs
(mBMSCs) (Fig. S8).
Animal work
Male C57BL/6J mice (Taconic) were given ad libitum normal chow
diet (Altromin® 132003; containing 6% fat, 30% protein, 63%
carbohydrate, and 7.7% sucrose) or 60 kcal% HFD (Research Diet
D12492; containing 35% fat, 26% protein, 26% carbohydrate, and
8.8% sucrose) at 8 weeks of age for a period of 12 weeks. Animals
were bred and housed under standard conditions (21 °C, 55%
relative humidity) on a 12-h light/12-h dark cycle. All experimental
procedures were approved by the Danish Animal Ethical
Committee (2017-15-0201-01210).
Glucose metabolic studies
A glucose tolerance test (GTT) was performed after 12 weeks of
HFD. For GTT, overnight-fasted mice were injected with 1 g·kg–1
D-glucose i.p. and glucose levels were measured at different
timepoints using a BREEZE® 2 meter (Bayer).
Isolation of BMSCs
BMSCs were isolated from the bones of the front and hind limbs of
C57BL/6J male mice (after 12 weeks of HFD) according to the
paper by Tencerova et al.28 following the steps of bone crushing,
collagenase digestion, and negative selection of CD45, CD31, and
Ter119 cells using microbeads (Miltenyi) according to the protocol
of Zhu et al. and Houlihan et al.49,50 Isolated BMSCs were cultured
in vitro, passaged, and used for subsequent analyses.
CFU assay
For assessment of CFUs, cells were plated at a density of 500 cells
in a 60-mm culture dish. After 14 days, colonies displaying more
than 50 cells were counted using crystal violet staining (Sigma-
Aldrich).
Flow cytometry
Immunophenotyping of BMSCs was performed by ﬂow cytometry.
Adherent cells were removed from ﬂasks using 0.05% trypsin
EDTA and incubated with Fc-mouse blocking reagent followed by
preconjugated antibodies for isotype controls and speciﬁc
markers (rat anti-mouse Sca-1-PE, cat. no. 553336; rat anti-mouse
CD140a-APC, cat. no. 562777; rat anti-mouse CD73-PE, cat. no.
550741; BD Biosciences and rat anti-mouse CD105-PE, cat. no.
120408; rat anti-mouse CD90.2-PE, cat. no. 140307; rat anti-mouse
CD44-PE, cat. no. 103024; BioLegend; rat anti-mouse CD53-FITC,
cat. no. 124705, BioLegend; Armenian hamster anti-mouse CD80
BV421, cat. no. 104725; BioLegend; rat anti-mouse CD134-APC, cat.
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no. 119413, BioLegend; rat anti-mouse CD141-PE, cat. no. 566338,
BD Bioscience, goat anti-mouse CD220-PE, cat. no. FAB1544P, R&D
Biosystems) used according to the manufacturers’ recommenda-
tions. The ﬂow cytometry was performed by a BD FACSAria II (BD
Biosciences) and analyzed by FlowLogic analysis software.
Statistical analysis
The statistical signiﬁcance of the differences in the means of the
investigated cell lines was determined by unpaired Student’s t test
or one-way ANOVA where appropriate using GraphPad Prism v
6.0c software. For all tests, P ≤ 0.05 was considered signiﬁcant. The
data are presented as the means ± SEM.
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